Vancouver, British Columbia, Canada, July 11, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce the appointment of Manpreet Dhillon as a director of the Company. Ms. Dhillon has over 20 years of international consulting experience specializing in implementing programs on economic empowerment, gender equality, and stakeholder engagement for international non-governmental organizations and governments within the United Nations system. Ms. Dhillon is the founder of Veza Global, a Canadian organization working globally to provide solutions to support employers, human resource practitioners and organizations as a whole to effectively address diversity, equity, inclusion and belonging in the communities they serve. Ms. Dhillon has significant experience as a strategic leader with expertise in equity, diversity, and inclusion programs, strategic planning, stakeholder engagement, brand development and leadership coaching. Ms. Dhillon holds BBA and MA degrees.

The Company also announces the resignation of Francisco Kent Carasquero as a director and Chief Financial Officer of the Company effective immediately. Current financial consultant Tammy Gillis has assumed the position of CFO, a role that she previously served at the Company. Ms. Gillis is a CPA, CMA with over 20 years' experience in the public markets and brings a comprehensive background in finance, reporting and regulatory requirements for junior exploration, manufacturing, bio-technology, and technology industries.

The Company is also pleased to announce that it has received approximately $731,000 in proceeds from the exercise of  4,300,464 share purchase warrants that were issued in May 2024 and repriced to $0.17 per share as previously announced on January 29, 2025. The proceeds will be used for general working capital purposes.

The Company also announces that its Board of Directors has granted stock options representing a total of 1,350,000 common shares to officers and directors of the Company.  These options were granted at an exercise price of $1.15, being the closing price on July 10, 2025, will vest in equal quarterly instalments over a one year period, and will expire on July 11, 2028.  All options were granted pursuant to the Company's Stock Option Plan.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.